A Phase 1/2 Study of Edasalonexent (CAT-1004) in Pediatric Patients With Duchenne Muscular Dystrophy

Trial Profile

A Phase 1/2 Study of Edasalonexent (CAT-1004) in Pediatric Patients With Duchenne Muscular Dystrophy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Edasalonexent (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MoveDMD
  • Sponsors Catabasis Pharmaceuticals
  • Most Recent Events

    • 10 Aug 2017 According to a Catabasis Pharmaceuticals media release, pending IRB approval, the open-label extension will be extended for an additional 52 weeks so that participating boys can continue to receive edasalonexent.
    • 23 Jun 2017 Results from Parts A and B will be presented at the 2017 Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference, according to a Catabasis Pharmaceuticals media release.
    • 11 May 2017 According to a Catabasis Pharmaceuticals media release, company intends to report results from Part C in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top